| NCT00265135 | Centocor, Inc. | Carcinoma, Renal Cell | 2003-08 | PHASE1|PHASE2 |
| NCT00311545 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Kidney Cancer | | PHASE2 |
| NCT00412321 | Centocor, Inc. | Lymphoma, Non-Hodgkin|Multiple Myeloma|Giant Lymph Node Hyperplasia | 2005-05 | PHASE1 |
| NCT00402181 | Centocor, Inc. | Multiple Myeloma | 2006-10 | PHASE2 |
| NCT05697510 | Nantes University Hospital | Acute Myeloid Leukemia (AML) | 2023-03-16 | PHASE1 |
| NCT00911859 | Janssen Research & Development, LLC | Multiple Myeloma | 2009-06 | PHASE2 |
| NCT06470971 | Yuanquan Yang | Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphatic System Neoplasm | 2024-07-09 | PHASE2 |
| NCT01309412 | Janssen Pharmaceutical K.K. | Multiple Myeloma | 2011-01 | PHASE1 |
| NCT01219010 | Janssen Research & Development, LLC | Monoclonal Gammopathy of Undetermined Significance|Multiple Myeloma|Plasma Cell Neoplasm | 2010-10 | PHASE1 |
| NCT00385827 | Centocor, Inc. | Cancer, Prostate | 2006-11 | PHASE2 |
| NCT02641522 | Carla Greenbaum, MD|Janssen Research & Development, LLC | Type 1 Diabetes | 2016-03-08 | EARLY_PHASE1 |
| NCT04616586 | RECORDATI GROUP|Syneos Health | Acute Respiratory Distress Syndrome|Lung Diseases|Pneumonia|Respiratory Tract Infections|Respiratory Tract Disease | 2020-11-13 | PHASE3 |
| NCT03315026 | Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC | Multiple Myeloma|AL Amyloidosis | 2017-12-14 | PHASE2 |
| NCT04330638 | University Hospital, Ghent|Belgium Health Care Knowledge Centre | COVID-19 | 2020-04-03 | PHASE3 |
| NCT00401843 | Janssen Research & Development, LLC | Multiple Myeloma | 2006-11-28 | PHASE2 |
| NCT07570173 | Merck Sharp & Dohme LLC | B-cell Acute Lymphoblastic Leukemia | 2026-05-08 | PHASE2|PHASE3 |
| NCT05665725 | Timothy Voorhees | Non-Hodgkin Lymphoma | 2023-01-31 | PHASE1 |
| NCT04329650 | Judit Pich Martínez | COVID-19 | 2020-04-15 | PHASE2 |
| NCT01266811 | Centocor, Inc. | Multiple Myeloma | 2011-07 | PHASE3 |
| NCT06990711 | Washington University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)|University of Utah | Antibody Mediated Rejection of Lung Transplant | 2025-11-06 | PHASE1 |
| NCT04838860 | RECORDATI GROUP | Idiopathic Multicentric Castleman´s Disease | 2021-03-31 | PHASE2 |
| NCT06352866 | Jack Khouri, MD | Multiple Myeloma|Cytokine Release Syndrome|Refractory Multiple Myeloma|Immune Effector Cell Associated Neurotoxicity Syndrome | 2025-01-01 | PHASE2 |
| NCT05684692 | Massachusetts General Hospital|United States Department of Defense|RECORDATI GROUP | Schwannomatosis|Schwannomas|Pain, Chronic | 2023-08-31 | PHASE2 |
| NCT02796859 | Brian Miller|Stanley Medical Research Institute | Schizophrenia|Psychotic Disorders | 2016-05 | PHASE1|PHASE2 |
| NCT06447376 | Taylor Brooks|Genmab|AbbVie|RECORDATI GROUP | Non-Hodgkin Lymphoma|Cytokine Release Syndrome | 2025-01-14 | PHASE1 |
| NCT04191421 | Emory University|Novartis|EUSA Pharma, Inc.|National Cancer Institute (NCI)|National Institutes of Health (NIH) | Metastatic Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8 | 2020-01-17 | PHASE1|PHASE2 |
| NCT01531998 | M.D. Anderson Cancer Center|Janssen Services, LLC | Myeloma | 2012-05 | PHASE1|PHASE2 |
| NCT06679829 | Memorial Sloan Kettering Cancer Center|RECORDATI GROUP | Multiple Myeloma | 2024-11-06 | PHASE2 |
| NCT01024036 | Janssen Research & Development, LLC | Multicentric Castleman´s Disease | 2010-03-18 | PHASE2 |
| NCT05316116 | H. Lee Moffitt Cancer Center and Research Institute|EUSA Pharma, Inc. | Large Granular Lymphocyte Leukemia | 2023-02-15 | EARLY_PHASE1 |
| NCT02805868 | Northwestern University|National Cancer Institute (NCI) | Myelofibrosis|Polycythemia Vera|Primary Myelofibrosis|Thrombocytopenia | 2016-06 | EARLY_PHASE1 |
| NCT01400503 | Janssen Research & Development, LLC | Multicentric Castleman´s Disease | 2011-04-01 | PHASE2 |
| NCT01513317 | Janssen Research & Development, LLC | Myelodysplastic Syndrome | 2011-11 | PHASE2 |
| NCT01484275 | Janssen Research & Development, LLC | High-risk Smoldering Multiple Myeloma | 2012-03-01 | PHASE2 |
| NCT04975555 | University of Alabama at Birmingham | Cytokine Release Syndrome|ICANS|Lymphoma, Non-Hodgkin|Multiple Myeloma|Acute Lymphoblastic Leukemia | 2021-11-15 | PHASE2 |
| NCT07106671 | Institute of Hematology & Blood Diseases Hospital, China | CRS - Cytokine Release Syndrome|Myeloma | 2025-08-10 | PHASE2 |